Aelis Farma Company Description

Aelis Farma SA, a clinical-stage biotechnology company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders.

It is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which is in phase I/II clinical trials to treat cognitive deficits observed in Down syndrome, as well as other cognitive impairments.

The company was incorporated in 2013 and is headquartered in Bordeaux, France.

Aelis Farma SA

Country	France
Founded	2013
Industry	Biotechnology
Sector	Healthcare
Employees	26
CEO	Pier Piazza

Contact Details

Address: 146 rue Lafaurie de Monbadon Bordeaux, 33 000 France
Phone	33 5 54 54 23 27
Website	aelisfarma.com

Stock Details

Ticker Symbol	AELIS
Exchange	Euronext Paris
Reporting Currency	EUR
ISIN Number	FR0014007ZB4
SIC Code	2836